~~<i id='A2A45B0F05'><strike id='A2A45B0F05'><tt id='A2A45B0F05'><pre id='A2A45B0F05'></pre></tt></strike></i>~~

Home» Wikipedia» Wikipedia

Wikipedia

author：focus 2025-09-30 10:06:21 Page View：96235

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： What AstraZeneca
Next article： 23andMe had bad news about my health. I wish a person had delivered it

explore

How to save PrEP access — and even expand it

UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

Sudan conflict brings new atrocities to Darfur as militias kill, rape, burn homes in rampages

File-SudaneserefugeeswhofledtheconflictinSudangatherMonday,July10,2023,attheZaboutrefugeeCampinGozBe

Psychedelics group wrestles with new pharma identity

OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

Alnylam reports growth in sales of rare disease treatments

KristofferTripplaar/SipaUSA/APAlnylamPharmaceuticalssaidThursdaythatsalesofitstreatmentsforraredisea